SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue and gross-margin outlook on stronger AI-platform demand, driving a major after-hours rally. Many traders welcomed the improved outlook and anticipated further gains or short covering, while others questioned whether the momentum would hold given the companys volatile history and lingering trust concerns.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results beat expectations, with rapid growth in its AI compute business and an aggressive buildout outlook driving strong enthusiasm. Traders are also debating whether the ambitious growth targets justify the valuation given heavy capital spending and uncertain execution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly profit beat expectations, but softer forward guidance and a reduced advertising-revenue outlook have intensified concerns about slowing growth and weighed on the shares. Traders are debating whether the ad business and content strategy can revive momentum, with many bearish while some view the selloff as overdone and are buying the dip.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp, high-volume rebound has put WULF in focus, with traders crediting CEO Paul Pragers CNBC interview and his explanation of the companys powered-shell model: leasing data-center infrastructure and power rather than buying GPUs. Bulls see its AI/HPC contracts and buildout as differentiating it from debt-heavy neocloud peers, while skeptics call the move a relief bounce and remain concerned about financing, execution, and the broader sector selloff.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential beyond epilepsy. Traders are split: some view the results as validation of the pipeline, while others cite the modest placebo-adjusted benefit and higher agitation-related discontinuations as reasons for caution as the early gains faded.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention amid a price rebound and breakout chatter, with bullish traders pointing to Zebecs reported payroll, card and network adoption, including its Stellar deployment. Skeptics counter that the token has struggled to sustain gains and say adoption must translate into stronger usage, volume and token demand.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Anticipation of Reddits upcoming quarterly results is driving discussion, with traders watching for evidence that ad growth and AI data licensing can support the stock. Bulls expect strong results to break its recent range, while bears point to insider selling, valuation concerns, and frustrating price action.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Middle East shipping and infrastructure threats that raise fears of oil-supply disruptions. Bulls see the geopolitical risk premium supporting crude, while bears expect it to unwind if shipping flows normalize or peace talks progress, fueling debate over the funds volatile moves.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals strong Q3 earnings beat was met with a sharp selloff, as traders focused on the narrowed da Vinci procedure-growth outlook and planned pricing cuts that could pressure revenue per procedure. The community is split between calling the reaction an overdone sell-the-news move and viewing slower growth and the litigation settlement as reasons for caution.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention for outperforming the cap-weighted S&P 500 as gains spread across more constituent stocks while mega-cap technology lagged. Traders view the strength as evidence of broader participation and rotation beyond tech, though some caution that the improvement may not last.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Syndax Pharmaceuticals, Inc. (Syndax or the Company) (NASDAQ: SNDX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)PR NewswireNEW YORK, Oct. 13, 2026SNDX shareholders saw the market open to losses of more than...

Syndax Pharmaceuticals Suffers Pipeline Blow

Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.read more...

Nasdaq Futures Slide As AI "Casino" Hangover Crushes Kospi; S&P Flat After JPM FICC Miss

Nasdaq Futures Slide As AI "Casino" Hangover Crushes Kospi; S&P Flat After JPM FICC Miss

 US futures are mixed with the Nasdaq lagging as the AI rout that started on Wall Street on Monday ricocheted through Asia, where the Kospi crashed as much as 7% after Broadcom's Hock Tan likened AI...

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. futures mixed; Syndax plunged 17% after its lung fibrosis trial missed its endpoint. Zhibao, Chaince, Six Flags and tech stocks also fell premarket.read more...

Syndax Reports Phase 2 Setback For Axatilimab In Idiopathic Pulmonary Fibrosis

(RTTNews) - Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate of decline in forced vital capacity (FVC...

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?  

Equity

Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis. 


Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of -22.22% and -11.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Neutral Sentiment

<ul class="summary-bullets"><li>The trial result ends Syndax’s plans to advance the drug further in idiopathic pulmonary fibrosis.</li><li>The company said the results do not affect ongoing trials of the same drug in other settings.</li><li>Axatilimab is already approved and sold as Niktimvo for chronic graft-versus-host disease, a serious complication that can follow stem-cell transplants.</li></ul><p>Syndax Pharmaceuticals (SNDX) shares tumbled 15% after hours on Monday after the company said its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis, a progressive and often fatal lung-scarring disease.</p><h2 class="st-heading-2">SNDX’s Trial Falls Short Of Key Lung Function Goal</h2><p>The 26-week MAXPIRe study enrolled about 145 patients across 62 sites in 14 countries. Participants were randomly assigned to receive axatilimab or placebo every two weeks, on top of any standard antifibrotic drugs they were already taking. The primary measure was the annualized rate of decline in forced vital capacity—essentially how quickly patients were losing the ability to push air out of their lungs.</p><p>Axatilimab did not slow that decline better than placebo. Secondary measures, including time to disease progression and quality-of-life scores, were also reported without evidence of benefit. The result ends Syndax’s plans to advance the drug further in idiopathic pulmonary fibrosis.</p><h2 class="st-heading-2">Drug Proves Safe But Company Drops IPF Plans</h2><p>Safety data looked relatively clean. Side effects leading to treatment discontinuation were low and similar between the drug and placebo arms, and no new safety concerns emerged. There were no treatment-related deaths. The most common side effects matched those seen in earlier studies of the medicine.</p><p>“The MAXPIRe trial did not meet its primary endpoint, and we are disappointed by this outcome given the promising scientific rationale in IPF,” said Nick Botwood, Syndax’s head of research and development and chief medical officer. The company said the results do not affect ongoing trials of the same drug in other settings.</p><h2 class="st-heading-2">Syndax Focus Shifts To Existing Blood Disorder Franchise</h2><p>Axatilimab is already approved and sold as Niktimvo for chronic graft-versus-host disease, a serious complication that can follow stem-cell transplants. Syndax and partner Incyte are testing it in combination regimens for newly diagnosed patients in that indication, with data expected later this year and in early 2028. Chief Executive Michael Metzger said the company remains focused on pushing both axatilimab and its other commercial drug, revumenib, into earlier lines of treatment.</p><p>Syndax’s announcement comes on the heels of Bristol Myers Squibb announcing mixed results from its late-stage IPF trial. The company said earlier on Monday that patients receiving a 60 mg twice-daily dose of admilparant showed statistically significant improvement in lung function, while those on the higher 120 mg twice-daily dose did not.</p><h2 class="st-heading-2">How Did SNDX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around SNDX stayed within neutral territory over the past 2 months, while message volume rose from normal to high levels.</p><p>A Stocktwits user said they bought more shares on the dip, highlighting that the drug has more data due this quarter and is already approved for other indications.</p><p><stembedurl>https://stocktwits.com/BioRich/message/666322476</stembedurl></p><p><a class="mention" data-mention="$SNDX" data-symbol-id="SNDX" href="https://stocktwits.com/symbol/SNDX" target="_blank">SNDX stock</a> fell by 21% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/chamath-palihapitiya-elon-musk-highlight-power-cooling-as-real-barriers-in-the-ai-race-where-everyone-competes-with-everyone/cZxINw3RB8F">Chamath Palihapitiya, Elon Musk Highlight Power, Cooling As Real Barriers In The AI Race Where ‘Everyone Competes With Everyone’</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis. 

SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$13.25
Prev Close	$13.09
Open	$13.20
Dividend Yield	0.00%
50-Day Moving Average	$18.18
Beta	1.15
Avg. Volume	1.83M
PE Ratio	-5.26

52-Week High	$25.59
52-Week Low	$12.80
Market Capitalization	$1.17B
EPS (Annual)	-$3.29
Price to Book	78.23
Revenue Per Employee	$578,362.42

Feed

News

Sentiment

Earnings

Fundamentals

Info

SNDX Fundamentals